Related Experiment Videos
Luteal contraception
1Department of Obstetrics and Gynaecology, University Medical School of Szeged, Hungary.
Human Reproduction (Oxford, England)
|February 1, 1988
Summary
Antiprogesterone medications like Mifepristone (RU 486) can prevent pregnancy by blocking progesterone action, acting as luteal contraception. This review covers their use as contraceptives and early pregnancy interventions.
Area of Science:
- Reproductive Endocrinology
- Pharmacology
- Contraception
Background:
- Progesterone is a critical reproductive hormone, essential for the luteal phase and pregnancy maintenance.
- Disrupting progesterone action can interfere with successful reproduction and early pregnancy.
- Antiprogesterones offer a mechanism for 'luteal contraception' by inhibiting progesterone's effects.
Purpose of the Study:
- To review clinical experience with antiprogestagens, specifically RU 486 (Mifepristone).
- To evaluate the efficacy and limitations of RU 486 in various reproductive control applications.
- To summarize the current status of 'contragestion' using antiprogestagen treatment.
Main Methods:
- Review of published clinical studies on RU 486 (Mifepristone).
- Analysis of RU 486's application as a post-coital contraceptive.
- Examination of RU 486's role as an implantation inhibitor, once-a-month pill, menstruation regulator, and early abortifacient.
Main Results:
- RU 486 (Mifepristone) has demonstrated effectiveness in multiple applications for reproductive control.
- Clinical data supports its use in post-coital contraception, implantation inhibition, and early pregnancy termination.
- The review discusses both the potential benefits and limitations associated with these uses.
Conclusions:
- Antiprogestagen treatment, exemplified by RU 486 (Mifepristone), represents a significant advancement in 'contragestion'.
- These agents offer versatile options for fertility regulation, including contraception and early pregnancy management.
- Further understanding of potentials and limitations is crucial for optimizing the clinical application of antiprogesterones.